OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
OPKO Health announced positive results from a Phase 3 clinical trial for somatrogon, a treatment for pediatric growth hormone deficiency, in Japan. The study met its primary and secondary objectives, demonstrating that somatrogon is comparably effective and safe when administered weekly versus the daily injection of GENOTROPIN. The somatrogon group showed a greater annual height velocity (9.65 cm/year) compared to GENOTROPIN (7.87 cm/year). With most adverse events being mild to moderate, the trial results represent a significant milestone for OPKO and may improve patient adherence and quality of life.
OPKO Health (NASDAQ: OPK) will participate in the Jefferies Virtual Healthcare Conference from June 2-4, 2020. Management is set to host one-on-one meetings with investors and will present on June 3 at 3:00 p.m. Eastern time. The presentation will be available via a live webcast and can be replayed afterward in the Investors section of OPKO's website.
OPKO is a biopharmaceutical and diagnostics company focused on leveraging its proprietary technologies to capture opportunities in rapidly growing markets. More information can be found at www.opko.com.
Summary not available.